ClinicalTrials.gg
Not yet recruitingNCT07939529PALACEUpdated Nov 16, 2026

People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness

A Phase 1 interventional study of Lenacapavir and Cabotegravir in HIV Viremia, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Not yet recruiting at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Viremia by National Institute of Allergy and Infectious Diseases (NIAID) — 1 open to participants now, 1 under way, none of them phase 3. Viremia · National Institute of Allergy and Infectious Diseases (NIAID).

Started
2028
the only one that year
Phase 1
2 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Viremia by National Institute of Allergy and Infectious Diseases (NIAID), this one is the only one that started in 2028, is one of 2 in phase 1, and was the 10th registered.

Viremia

58 studies on the registry are indexed under Viremia; 13 are open to participants now.

Browse Viremia studies →

Open to participants now

1 of the 10 studies in Viremia by National Institute of Allergy and Infectious Diseases (NIAID) is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 10 Viremia studies recruiting now, 4 (40%) set no upper age limit and 4 (40%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Viremia by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.

03

Conditions studied

  • HIV Viremia

Browse trials for

Keywords

  • HIV-1
  • Lenacapavir
  • Cabotegravir
  • Long-acting antiretroviral therapy
  • Rilpivirine resistance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented -1 infection
  • Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
  • HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
  • Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
  • At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
  • Adequate laboratory parameters within 60 days prior to study entry:

    • >600/mm3
    • ≥7.0 g/dL
    • count >50,000/μL
    • and ALT ≤3 ×
    • Estimated >15 mL/min/1.73 m²
  • For participants of , negative pregnancy test at screening and within 24 hours prior to study entry
  • Ability and willingness to provide
  • Connected to a medical clinic with access to HIV care and antiretroviral therapy

Exclusion criteria

Exclusion Criteria:

  • Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
  • Active infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
  • Class C cirrhosis
  • No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
  • Prior use of lenacapavir
  • Receipt of immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
  • Serious medical or psychiatric condition
  • Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
  • Current pregnancy or breastfeeding
  • Known allergy, , or intolerance to cabotegravir, lenacapavir, or formulation components
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Long-Acting Lenacapavir Plus Long-Acting Cabotegravir

    Drug: Lenacapavir · Drug: Cabotegravir · Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide

Interventions

  • Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation.

  • Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses.

  • DrugBictegravir/Emtricitabine/Tenofovir Alafenamide

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir

    Time frame: Baseline through Week 48

Secondary outcomes

  1. Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis

    Time frame: Week 48

  2. Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis

    Time frame: Week 48

  3. Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure

    Time frame: Week 48

  4. Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir

    Time frame: Baseline through Week 96

  5. Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance

    Time frame: Baseline through Week 96

  6. Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir

    Time frame: Baseline through Week 96

  7. Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis

    Time frame: Week 96

  8. Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis

    Time frame: Week 96

  9. Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure

    Time frame: Week 96

  10. Percentage of on-time long-acting injections

    Time frame: Through Week 48 and through Week 96

  11. Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir

    Time frame: Baseline through Week 48 and through Week 96

  12. Plasma trough concentrations of lenacapavir and cabotegravir

    Time frame: Through Week 48 and through Week 96

  13. Change in CD4 cell count from baseline

    Time frame: Week 48 and Week 96

  14. Participant-reported treatment satisfaction

    HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment.

    Time frame: Week 48 and Week 96

  15. Change in quality-of-life scores from baseline

    Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: Week 48 and Week 96

  16. Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline

    Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Week 48 and Week 96

  17. Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy

    Time frame: Baseline through Week 48

  18. Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis

    Time frame: Week 48

  19. Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis

    Time frame: Week 48

  20. Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure

    Time frame: Week 48

07

Study locations

24 sites
  • Alabama (Site ID: 31788)
    Birmingham, Alabama 35222, United States
  • University of California, Los Angeles CARE Center (Site ID: 601)
    Los Angeles, California 90035, United States
  • UCSD Antiviral Research Center (Site ID: 701)
    San Diego, California 92103, United States
  • University of California, San Francisco (Site ID: 801)
    San Francisco, California 94110, United States
  • Harbor University of California Los Angeles Center (Site ID: 603)
    Torrance, California 90502-2052, United States
  • University of Colorado Hospital (Site ID: 6101)
    Aurora, Colorado 80045, United States
  • Whitman-Walker Institute, Inc. (Site ID: 21791)
    Washington D.C., District of Columbia 20032, United States
  • Northwestern University (Site ID: 2701)
    Chicago, Illinois 60611, United States
  • Johns Hopkins University (Site ID: 201)
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital (Site ID: 101)
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
    Boston, Massachusetts 02115, United States
  • New Jersey Medical School Clinical Research Center (Site ID: 31786)
    Newark, New Jersey 07103, United States
  • Weill Cornell Chelsea (Site ID: 7804)
    New York, New York 10010, United States
  • Weill Cornell Uptown (Site ID: 7803)
    New York, New York 10010, United States
  • Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
    New York, New York 10032, United States
  • Chapel Hill (Site ID: 3201)
    Chapel Hill, North Carolina 27599-7215, United States
  • Greensboro (Site ID: 3203)
    Greensboro, North Carolina 27401-1020, United States
  • Cincinnati Clinical Research Site (Site ID: 2401)
    Cincinnati, Ohio 45267-0405, United States
  • Case Clinical Research Site (Site ID: 2501)
    Cleveland, Ohio 44106, United States
  • Ohio State University (Site ID: 2301)
    Columbus, Ohio 43210, United States
  • University of Pittsburgh (Site ID: 1001)
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt Therapeutics (VT) (Site ID: 3652)
    Nashville, Tennessee 37204, United States
  • Houston Advancing Research Team (Site ID: 31473)
    Houston, Texas 77030, United States
  • University of Washington Positive Research (Site ID: 1401)
    Seattle, Washington 98104, United States
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie results in the publication after deidentification

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH

Access criteria: With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG. For what types of analyses? To achieve aims in the proposal approved by the ACTG. By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2028; primary completion for Aug 2029, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Feb 1, 2028
Primary completionEst.
Aug 31, 2029
CompletionEst.
Oct 26, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939529
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Feb 1, 2028 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Oct 26, 2030 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenacapavir · Cabotegravir

Start the discussion